Funding Details
- Awarder
- Inbox
- Date Award
- May 15, 2025
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
Company Info
- Traction
- Numab's immuno-oncology therapeutic NM26 entered the clinic and the company started a collaboration with Kaken Pharmaceuticals.
- Organizations Involved
- Johnson & Johnson
- Founders
- David Urech
- Company Description
- Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases.
- Market
- Immunology and Oncology
- Location
-
Horgen,
Switzerland
- Coinvestors
- Cormorant Asset Management, Forbion, HBM Healthcare Investment, Novo Holdings, BVF Partners L.P., Octagon Capital Advisors LP, RTW Investments, BlackRock
Links